Skip to main content


Rainer Hubmann
Mag. Dr. Rainer Hubmann, PhDPrincipal Investigator

Department of Medicine I (Division of Hematology and Hemostaseology)
Position: Research Assistant

ORCID: 1-6891-646X
T +43 1 40400 52830


Genetics; Leukemia; Receptors, Notch; Therapeutics

Research group(s)

  • Comprehensive Cancer Center Vienna / Drug & Target Screening Unit

Research interests

The main focus of my research is elucidating the clonal evolution/maintenance of leukemia/solid tumor cells with special emphasis on the NOTCH2 signaling Network in chronic lymphocytic leukemia (CLL). The cancer initiating oncogene NOTCH2 is frequently deregulated in neoplastic cells, making NOTCH2 an ideal target for therapeutic interventions. We have recently shown that the Aspergillus derived secondary metabolite gliotoxin is a potent nuclear NOTCH2 inhibitor and efficiently targets neoplastic cells in vitro and in a melanoma xenotransplant mouse model in vivo. We are also screening whole genome sequencing data (WGS) for NOTCH2 gain of function (GOF) mutations/aberrations/haplotypes with special emphasis on singel nucleotide variation (SNV) combinations leading to the loss of the NOTCH2 negative regulatory region (NRR) by aberrant splicing. The most frequent NOTCH2 SNV combinations will be the basis for the development of RFLP assays as predictive/diagnostic tool for NOTCH2 associated malignancies.

Techniques, methods & infrastructure

Cocultur models to mimic the CLL Tumor microenvironment. FACS, RT-PCR, EMSA, Western bloting, sequence analysis, gene silencing for functional studies with siRNA, drug screening assays.

Selected publications

  1. Hubmann, R. et al., 2012. Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol, 160(5), pp.618-629. Available at:
  2. Hubmann, R. et al., 2010. NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. British Journal of Haematology, 148(6), pp.868-878. Available at:
  3. Duechler, M. et al., 2004. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia, 19(2), pp.260-267. Available at:
  4. Hubmann, R. et al., 2002. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood. 2002 May 15;99(10):3742-7.
  5. Hubmann, R. et al., 2017. Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model. Frontiers in Pharmacology, 8. Available at: